Abstract
Objective : This is a retrospective analysis of 25 children with severe Guillaln-Barre syndrome admitted to our PICU.Method : All children were treated with intravenous immunoglobulins (IVIG) in a dose of 2 g/kg body weight over 2–5 days in addition to supportive and respiratory care. Seventeen children were elective admissions to the PICU whereas 8 children were transferred from other hospitals in a critical condition. Five of 8 of the late referrals died as compared to none of the elective admissions.Result : All 8 of the late referrals required mechanical ventilation as against 3 of the 17 elective admissions. Mean duration of PICU stay in the late referrals was 27 days as compared to 15 days in the elective admissions.Conclusion : The authors concur with previously published reports, that early use of IVIG could reduce the mortality and the need for intubation and mechanical ventilation.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Evans OB, Vedanarayanan V. Gufflain-Barre Syndrome.Pediatr Rev 1997; 18: 10–16.
Shahar E, Murphy EG, Roifman CM. Benefit of intravenously administered serum immunoglobulin in patients with Guillain-Barre syndrome.J Pediatr 1990; 116: 141–144.
Notarangelo LD, Duse M, Tiberti Set al. Intravenous immunoglobulin in two children with Guillain-Barre syndrome.Eur J Pediatr 1993; 152: 372–374.
Suri M, Suri ML, Shahani Intravenous.imrnunoglobulin (IVIG) therapy in children with acute inflammatory demyelinating polyneuropathy (AIDP).Neurology 1993; 43(Suppl 2): 347.
Al-Qudah A. Immunoglobulins in the treatment of Guillain-Barre syndrome in early childhood.J Child Neurol 1994; 9: 178–180.
Vasjar J, Sloane A, Wood E, Murphy EG. Plasmapheresis vs immunoglobulin treatment in childhood Guillain-Barre syndrome.Arch Pediatr Adolesc Med 1994; 148: 1210–1212.
Shahar E, Shorer Z, Roifman CMet al. Immune globulins are effective in severe pediatric Guillain-Barre syndrome.Pediatr Neurol 1997; 16: 32–36.
Reisin RC, Poicecha J, Rodriguez Eet al. Severe Guillain-Barre syndrome in childhood treated with human immune globulin.Pediatr Neurol 1996; 14: 308–312.
Abd-Allah SA, Jansen PW, Ashwal S, Perkin RM. Intravenous immunoglobulin as therapy for pediatric Guillain-Barre syndrome.J Child Neur 1997; 12: 376–380.
Kanara G, Ozon A, Vasjar J, Castagva L, Secmear G, Topaloghu J. Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome.Eur J Pediatr Neurol 1997; 1: 7–12.
Singhi SC, Jayshree M, Singhi P, Banerjee S, Prabhakar S. Intravenous immunoglobulin in very severe childhood Guillain-Barre syndrome.Ann Trop Pediatr 1999; 19(2): 167–174.
Asbury AK, Arnason BG, Karp HRet al. Criteria for diagnosis of Gufflain-Barre syndrome.Ann Neurol 1978; 3: 565–566.
Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome.Ann Neurol 1990; 27(Suppl): S 21–24.
Korinthenberg R, Monting JS. Natural history and treatment effects in Guillain-Barre syndrome: a multicentre study.Arch Dis Child 1996; 4: 281–287.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shanbag, P., Amirtharaj, C. & Fathak, A. Intravenous immunoglobulins in severe Guillian-Barre syndrome in childhood. Indian J Pediatr 70, 541–543 (2003). https://doi.org/10.1007/BF02723152
Issue Date:
DOI: https://doi.org/10.1007/BF02723152